Dr Martin Hall, Analyst at Stanford Capital Partners, talks to Proactive Investors on the continued inherent value of ImmuPharma and its continued support by its Lupuzor partner, Avion Pharmaceuticals, as they expand their collaboration partnership to potentially bring in near term revenues – 1st December 2022

2nd December 2022 - 12:14 pm
Share this article